We partner with healthcare and biotechnology companies to navigate critical moments by communicating the science, strategy, and value behind their innovation.
New York City
Joined November 2008
- Tweets13.4K
- Following1.4K
- Followers1.6K
- Likes9.1K
Pinned Tweet
The new Russo Partners website is live. Explore our Insights hub, the Russo Edge Podcast, and how we work across media, IR, digital, and strategy to translate complex science into clear stories. bit.ly/3WtK0Il
#Biotech #LifeSciences #Healthcare #PR
Russo Partners retweeted
In a new @ClinicalLeader1 interview, our CEO @KevinCaldweII explains why Ossium took a multi-center approach from its earliest study.
To date, 29 patients have been treated with Ossium’s organ donor-derived bone marrow at roughly half as many centers, each using the conditioning regimens and post-transplant care its team already knew. The goal was to generate data that reflects real-world transplant practice.
We're now carrying that approach into PRESERVE II, a 300-patient, three-arm study that begins enrollment in 2027.
Read the full interview: clinicalleader.com/doc/ossiu…
Russo Partners retweeted
What if the future of diabetes treatment depends on WHERE a medicine acts - not just which medicine we use?
On this episode of @ProgressPotent1 I'm joined by Robert Geho, Co-Founder and CEO of @Diasome Pharmaceuticals
For decades, insulin therapy has helped millions of people manage diabetes. But conventional injected insulin reaches the general circulation before the liver -the organ that plays a central role in regulating glucose metabolism.
Diasome is developing a different approach.
Its proprietary Hepatocyte-Directed Vesicle (HDV) technology is designed to direct insulin toward liver cells, with the goal of improving glucose regulation while reducing hypoglycemia.
In our conversation, we explore:
🧬 Why the liver is so important to normal insulin physiology;
🔬 How HDV technology is designed to change insulin delivery;
📊 What Diasome's Phase 2b OPTI-2 results tell us;
💉 Whether liver-targeted insulin could complement today's insulin therapies;
⚖️ Why the company is also investigating HDV-based approaches to GLP-1 and serotonin signaling;
And we'll tackle a bigger question: Could more precise drug delivery open new possibilities for treating metabolic disease?
The science is fascinating. The clinical evidence compelling. And the next steps will determine whether this approach can make a meaningful difference for patients.
Watch now - youtube.com/watch?v=jx6ZfxpO…
#Diabetes #Biotechnology #DrugDelivery #MetabolicHealth #MedicalInnovation @russopartners
🤖 Made with AI
Russo Partners retweeted
🎉 2 weeks until Impact Night!
There's still time to join NYC's life science community on Nov 4 at Time Out Market, Union Square for a night that turns connection into change.
🎟️ Individual $500 | Party of 3 $1,350
👉host.nxt.blackbaud.com/regis…
#ImpactNight #NYC #LifeSciences
Russo Partners retweeted
We're proud to be named @GenomeWeb's 2026 Best Places to Work—for the second year in a row!
This recognition is especially meaningful because it comes directly from our employees. It reflects the collaboration, shared purpose and supportive culture that bring our mission to life everyday.
To our entire Lucid Diagnostics team, thank you for the dedication, passion and commitment you bring to our work and to one another. We're proud of what we've built together and excited for what's ahead.
#BestPlacesToWork #Team
Russo Partners retweeted
Nice to see our partner highlighting RPE cell therapy. At #AAO2026, #retina specialists heard firsthand about treatments that can make a meaningful difference for #dryAMD patients.
$LCTX #OpRegen #ReplaceandRestore @CEO_Culley
Russo Partners retweeted
Thrilled to announce that Revuforj® (revumenib) was named one of @TIME's Best Inventions of 2026!
We’re honored to be recognized for advancing the next generation of innovative therapies for patients who need them most. Today and always, we thank the Syndaxers, clinicians, investigators and patients who have played a pivotal role in shaping the future of medicine.
Learn more:
ir.syndax.com/news-releases/…
#TIMEBestInventions
Russo Partners retweeted
Are there some things you don't know about Lambert-Eaton myasthenic syndrome (LEMS)? LEMS is considered a rare disease, and since some of its symptoms are similar to other diseases, it is frequently misdiagnosed.
Learn more: catalystpharma.com/lems
#LEMS #raredisease
Russo Partners retweeted
$LCTX congratulates @ca_navntoft and the Eriksholm Research Center for their review of the current status of cell therapy for restoring auditory nerve function, which highlights the importance of combining #celltherapy with surgical approaches to help people with hearing loss.
We look forward to continued progress on our ReSonance® (ANP1) program, an auditory neuronal cell transplant program to treat hearing loss.
Read the full article: sciencedirect.com/science/ar…
#ReplaceAndRestore #HearingLoss | @CEO_Culley
Russo Partners retweeted
Coya today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (#ALS).
We plan to initiate the OLE in response to requests from ALSTARS investigators and study participants. “The strong interest from investigators and participants in continuing treatment beyond the current 48-week study period underscores the importance of providing continued access to COYA 302 for eligible participants in the ALSTARS trial,” said Dr. Fred Grossman, DO, FAPA, our President and Chief Medical Officer.
For more details: businesswire.com/news/home/2…
#EndALS
Russo Partners retweeted
Catalyst offers a range of programs designed to help ensure patients can access the treatment they need. Learn more about our affordable, accessible treatment support through Catalyst Pathways: yourcatalystpathways.com/dmd….
#CatalystPathways #support #raredisease
Russo Partners joined Miami Biotech Collective and @MiamiHurricanes for Building Championship Teams in Sports and Biotech panel moderated by our own @SolomonsWisdom. @davidschull and Ignacio Guerrero-Ros, Ph.D. also attended. Thanks for a great evening! #MiamiBiotech #LifeSciences #Biotech
Russo Partners retweeted
More than 90% of patients at risk for esophageal precancer never get screened with endoscopy.
Many have been managing their heartburn with medication for years, unaware that chronic reflux can put them at risk for esophageal precancer and cancer. Without screening, these patients can go undetected until the disease has progressed.
@EsoGuard_Test is helping change that. This non-endoscopic triage test helps clinicians identify which at-risk patients are more likely to have precancerous changes and may benefit most from endoscopy.
The result? Better insight before endoscopy, higher diagnostic yield, and more clinically actionable findings.
Connect with the Lucid Diagnostics team at #ACG2026 to learn how EsoGuard can help you identify more at-risk patients and make endoscopy more effective.
#GITwitter
Russo Partners retweeted
Today, we announced that the first participant has been dosed in RESTORE, our Phase 3 registrational study evaluating NVG-291 in chronic spinal cord injury.
Read more:
nervgen.com/nervgen-announce…
#SCI #SpinalCordInjury
Last month, team members Tierney Sovic and Nic Johnson attended investor conferences hosted by @HCWCO, @rwbaird, and Moody Capital. Thank you to everyone that made time to connect! #InvestorRelations #Biotech #LifeSciences
Russo Partners retweeted
Boston, we're just one week away from @BloodCancerUtd's Light The Night!
We hope you'll join us as we walk to fund critical blood cancer research, advocate for patients and shine a ray of hope for those navigating blood cancers.
As returning national sponsors, we can’t wait to welcome you under the Syndax tunnel at the finish line!
Be the light and join our team here:
pages.lls.org/ltn/ma/BostonL…
#BloodCancerUnitedLightTheNight #WeFlyHigherTogether
Russo Partners retweeted
Aprea CEO Oren Gilad joined NanoCap Podcast to discuss targeted cancer therapies, the science behind synthetic lethality, and Aprea’s latest clinical progress. Hear how innovative approaches could help advance new treatment options for patients: bit.ly/478AikZ $APRE
Russo Partners retweeted
Your seat at Impact Night 2026 is waiting 🎟️ Join NYC's life science community for food, celebration & connection!
📅 Nov 4, 6:30–9:30pm
📍 Time Out Market Union Square
🎟️ Individual $500 | Party of three $1,350
👉 host.nxt.blackbaud.com/regis…
#NYCLifeSciences #LifeSciences #NYC
#SocialMedia is now key in reaching investors and potential partners.
Last month, our President @davidschull moderated "Amplify Your Impact: Social Media Strategies for Biopharma Success," a Virtual Salon hosted by Demy-Colton and @Biotechgate.
Watch: youtube.com/watch?v=gdd3_880…
Russo Partners retweeted
More sites are opening for the ALISCA®-Lung2 clinical trial for patients with small cell lung cancer. #SCLC #LCSM #alisertib #CancerClinicalTrials
Learn more and find a participating site near you: bit.ly/ALISCA-Lung2
ALT Puma Biotechnology logo, collage of patients with oncologists, Image text reads: ALISCA®-Lung2: A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer. Alisertib is an investigational drug and it has not been approved by any health authority. Safety and efficacy of alisertib have not been established.